AOD-9604
Also known as: Anti-Obesity Drug 9604, GH Fragment 176-191 Modified
Overview
AOD-9604 is a modified peptide fragment corresponding to amino acids 176-191 from the C-terminal region of human growth hormone, with a stabilizing tyrosine modification. It was engineered to isolate the fat-metabolizing properties of growth hormone without producing growth-promoting, insulin-sensitizing, or IGF-1-stimulating effects. Preclinical research demonstrates significant fat reduction, particularly visceral and subcutaneous fat, via beta-3 adrenergic receptor upregulation.
Mechanism of Action
AOD-9604 does not bind growth hormone receptors. Instead, it preferentially accumulates in adipose tissue and interacts with beta-3 adrenergic receptors on fat cell membranes. This activates adenylyl cyclase, raising intracellular cAMP levels, which activates protein kinase A, which phosphorylates and activates hormone-sensitive lipase to break down stored triglycerides. Simultaneously, AOD-9604 downregulates lipogenic enzymes, creating dual fat-loss pressure. In obese mice, it restored suppressed beta-3 AR expression to lean levels, confirming the mechanistic link.
Potential Benefits
- Fat reduction without affecting glucose regulation or insulin sensitivity
- Dual mechanism: increases lipolysis while inhibiting lipogenesis
- Selective targeting of visceral and subcutaneous adipose tissue
- No IGF-1 stimulation, avoiding growth-promoting side effects
- Muscle mass preservation during fat loss
- 50%+ reduction in weight gain in obese mouse models over 19 days
- Beta-3 AR receptor upregulation in adipose tissue
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 300-500 mcg/day |
| Beginner | 300 mcg/day |
| Intermediate | 500 mcg/day |
| Advanced | 500-1000 mcg/day split into two doses |
| Cycle Duration | 4-12 weeks |
| Cycle Off | 4 weeks |
Best dosed in a fasted state or 2-3 hours post-meal to avoid insulin interference with lipolytic signaling. Morning or pre-cardio dosing is common. Does not significantly impact GH or IGF-1 levels at standard doses.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Primary route; consistent fat-targeting lipolytic effects; inject into abdominal subcutaneous fat
Oral Low
Oral trials conducted in human safety studies; lower bioavailability but studied in Phase IIb trials for obesity treatment
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving AOD-9604:
Fat Loss Stack
Targeted lipolysis combined with GH-driven fat metabolism and anabolism
AOD-9604 provides direct lipolysis activation while GH axis peptides drive broader metabolic improvements and muscle preservation.
Body Recomposition Stack
Dual-pathway fat loss through GH fragment lipolysis and GLP-1 appetite suppression
Complementary mechanisms; AOD-9604 targets lipid metabolism; Semaglutide reduces caloric intake via central satiety.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 2mg, 5mg |
|---|---|
| BAC Water | 1-2ml per 2mg vial |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Shelf Life | 28 days refrigerated |
Need exact syringe measurements?
Amino Acid Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (amino acids 176-191 of HGH with Tyr modification)
Side Effects & Safety
- Generally well-tolerated in clinical studies
- Injection site reactions
- Headache reported in some subjects
- No significant cardiovascular or metabolic adverse events at therapeutic doses
Synergistic Compounds
The following compounds have been studied alongside AOD-9604 for potential complementary or synergistic effects:
Learn More
References & Further Reading
- [object Object]
- [object Object]
- [object Object]